p53 in relation to therapeutic outcome of locoregional chemotherapy in pancreatic cancer

Annals of the New York Academy of Sciences

Volumn 880, Issue , 1999, Pages 281-287

  Gansauge, Frank ^a   Gansauge, Susanne ^a   Link, Karl H ^a   Beger, Hans G ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; MITOXANTRONE; PROTEIN P53;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANGIOGRAPHY; CATHETER; CELIAC ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; MALE; PANCREAS CANCER; PROTEIN EXPRESSION; SURVIVAL TIME;

EID: 0032774823     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb09532.x     Document Type: Conference Paper

References (12)

1. 1. GUDIONSSON, B. 1987. Cancer of the pancreas: 50 years of surgery. Cancer 60: 2284-2303.
2. 2. NITECKI, S.S., M.G. SARR, T.V. COLBY & J.A. VAN HEERDEN. 1995. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Ann. Surg. 221: 59-66.
3. 3. BEGER, H.G. & R. BITTNER. 1985. Surgical treatment in carcinoma of the head of the pancreas. Z. Gastroenterol. 23: 240-247.
4. 4. TREDE, M. 1987. The surgical treatment of pancreatic carcinoma. Surgery 97: 28-34.
5. 5. YEO, C.J., R.A. ABRAMS, L.B. GROCHOW, T.A. SOHN, S.E. ORD, R.H. HRUBAN, M.L. ZAHURAK, W.C. DOOLEY, J. COLEMAN, P.K. SAUTER, H.A. PITT, K.D. LILLEMOE & J.L. CAMERON. 1997. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann. Surg. 225: 621-627.
6. 6. TSUCHIYA, R., T. TOMIOKA, K. IZAWA, T. NODA, K. YAMAMOTO, T. TSUNODA, N. HARADA, T. YAMAGUCHI, R. YOSHINO & T. MIYAMAOTO. 1986. Collective review of small carcinomas of the pancreas. Ann. Surg. 203: 77-81.
7. 7. GANSAUGE, F., K.H. LINK, N. RILINGER, R. KUNZ & H.G. BEGER. 1995. Regional chemotherapy in advanced pancreatic carcinoma. Med. Klin. 90: 501-505.
8. 8. GANSAUGE, S., F. GANSAUGE & H.G. BEGER. 1996. Molecular oncology in pancreatic cancer. J. Mol. Med. 74: 313-320.
9. 9. GANSAUGE, F., S. GANSAUGE, J. MULLER, E. SCHMIDT & H.G. BEGER. 1998. Prognostic significance of molecular alterations in pancreatic carcinoma: an immunhistological study. Langenbecks Arch. Chir. 383: 152-155.
10. 10. HARADA, N., S. GANSAUGE, F. GANSAUGE, H. GAUSE, S. SHIMOYAMA, T. IMAIZUMI, T. MATTFELDT, M.H. SCHOENBERG & H.G. BEGER. 1997. Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin dependent kinase inhibitor p21WAFI in pancreatic cancer. Br. J. Cancer 76: 299-305.
11. 11. GANSAUGE, F., K.H. LINK, N. RILINGER, R. KUNZ & H.G. BEGER. 1996. Adjuvant regional chemotherapy in locally advanced pancreatic cancer. Chirurg 67: 362-365.
12. 12. ISHIKAWA, O., H. OHIGASHI & Y. SASAKI. 1994. Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am. J. Surg. 168: 361-364.